Synaffix B.V. and Emergence Therapeutics AG have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix’s proprietary antibody drug conjugate (ADC) technologies including GlycoConnect, HydraSpace and SYNtecan E linker-payload.   Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on commercial sales. The first program will commence at signa...